Partner Level
Company Headquarters
201 Industrial Rd.
Suite 410
San Carlos, CA 94070
Visit Site

Natera has developed Signatera, a personalized ctDNA test for molecular residual disease (MRD) detection and recurrence monitoring in patients previously diagnosed with cancer. Signatera’s tumor-informed assay is optimized to detect low levels of ctDNA, with high accuracy in identifying MRD and recurrence with longer lead times. Signatera has been clinically validated in multiple cancer types including colorectal, non-small cell lung, breast, and bladder cancers. Look deeper at

© 2021 FLASCO | Premium Website Design by The HDG